FDA NewsImmunotherapyNewsworthy

Cancer Immunotherapy Drugs Approved by the FDA Since 2015

This article includes immunotherapies approved through May 2017.

June 2017 Cancer Immunotherapy

Immunotherapies have been approved by the FDA for more than a decade, but the past 2 years stand out as the period when immunotherapy became a familiar concept in the United States, with the explosion of new therapies that involve the immune system approved by the FDA for many types of cancer.

The Table highlights cancer immunotherapy drugs approved by the FDA between January 2015 and May 2017, focusing on anti-PD-1 and anti-PD-L1 checkpoint inhibitors; antibodies such as monoclonal antibodies and anti-CTLA-4 antibodies; immunomodulatory drugs; and viral cancer therapies.

Cancer Immunotherapy Drugs Approved by the FDA Since 2015

Recommended For You
FDA NewsNewsworthyProstate Cancer
Erleada First Drug Approved for Patients with Nonmetastatic Prostate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Breast CancerFDA NewsNewsworthy
Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.